Elanco Animal Health Inc - Aug 27, 2021 Form 4 Insider Report for Kindred Biosciences, Inc. (KIN)

Role: 10%+ Owner
Signature: /s/ Todd Young Todd Young as Executive Vice President and Chief Financial Officer of Elanco Animal Health Incorporated
Stock symbol: KIN
Transactions as of: Aug 27, 2021
Transactions value $: $420,957,677
Form type: 4
Date filed: 8/30/2021, 09:08 AM
Previous filing: Jun 25, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KIN	Common Stock, par value $0.0001	Purchase	$421M	+45.5M		$9.25	10K	Aug 27, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Elanco Animal Health Inc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger, dated as of June 15, 2021 and as amended on June 30, 2021, by and among Elanco Animal Health Incorporated, Knight Merger Sub, Inc., a wholly owned subsidiary of Elanco Animal Health Incorporated ("Merger Sub"), and Kindred Biosciences, Inc. ("KindredBio"), Merger Sub merged with and into KindredBio (the "Merger") on August 27, 2021. Upon completion of the Merger, each share of common stock of KindredBio that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. Consequently, upon the consummation of the Merger on August 27, 2021, Elanco became the owner of 10,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation.

Content

Pursuant to the Agreement and Plan of Merger, dated as of June 15, 2021 and as amended on June 30, 2021, by and among Elanco Animal Health Incorporated, Knight Merger Sub, Inc., a wholly owned subsidiary of Elanco Animal Health Incorporated ("Merger Sub"), and Kindred Biosciences, Inc. ("KindredBio"), Merger Sub merged with and into KindredBio (the "Merger") on August 27, 2021. Upon completion of the Merger, each share of common stock of KindredBio that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. Consequently, upon the consummation of the Merger on August 27, 2021, Elanco became the owner of 10,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation.